$ESTA
ESTABLISHMENT LABS HOLDINGS INC. Stock $esta

$esta Overview Financials Valuation SEC Filings Company Website

2020 Q1 Form 10-Q Financial Statement

#000168875720000027 Filed on May 08, 2020

Income Statement

Concept	2020 Q1	2019 Q1
Revenue	$24.48M	$20.78M
YoY Change	17.82%	40.24%
Cost Of Revenue	$9.003M	$9.526M
YoY Change	-5.49%	38.04%
Gross Profit	$15.48M	$11.25M
YoY Change	37.56%	42.16%
Gross Profit Margin	63.22%	54.15%
Selling, General & Admin	$18.98M	$16.06M
YoY Change	18.24%	85.66%
% of Gross Profit	122.65%	142.69%
Research & Development	$4.199M	$3.584M
YoY Change	17.16%	66.93%
% of Gross Profit	27.13%	31.85%
Depreciation & Amortization	$20.00K	$21.00K
YoY Change	-4.76%	-12.5%
% of Gross Profit	0.13%	0.19%
Operating Expenses	$23.18M	$19.64M
YoY Change	18.04%	81.94%
Operating Profit	-$7.705M	-$8.388M
YoY Change	-8.14%	191.25%
Interest Expense	$2.146M	$2.242M
YoY Change	-4.28%	3.27%
% of Operating Profit
Other Income/Expense, Net	-$6.190M	-$304.0K
YoY Change	1936.18%	-255.9%
Pretax Income	-$17.52M	-$10.74M
YoY Change	63.22%	64.65%
Income Tax	$231.0K	$44.00K
% Of Pretax Income
Net Earnings	-$17.75M	-$10.78M
YoY Change	64.7%	65.07%
Net Earnings / Revenue	-72.52%	-51.88%
Basic Earnings Per Share
Diluted Earnings Per Share	-$790.3K	-$525.9K
COMMON SHARES
Basic Shares Outstanding	23.33M shares	20.39M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2020 Q1	2019 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$93.60M	$43.10M
YoY Change	117.17%	553.03%
Cash & Equivalents	$93.60M	$43.14M
Short-Term Investments
Other Short-Term Assets	$7.200M	$4.700M
YoY Change	53.19%	20.51%
Inventory	$25.51M	$23.75M
Prepaid Expenses
Receivables	$21.62M	$20.12M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$147.9M	$91.72M
YoY Change	61.25%	120.47%
LONG-TERM ASSETS
Property, Plant & Equipment	$16.24M	$13.20M
YoY Change	22.97%	-1.48%
Goodwill	$465.0K	$465.0K
YoY Change	0.0%
Intangibles	$3.465M	$3.248M
YoY Change	6.68%
Long-Term Investments
YoY Change
Other Assets	$362.0K	$325.0K
YoY Change	11.38%	8.33%
Total Long-Term Assets	$20.53M	$17.24M
YoY Change	19.07%	-0.92%
TOTAL ASSETS
Total Short-Term Assets	$147.9M	$91.72M
Total Long-Term Assets	$20.53M	$17.24M
Total Assets	$168.4M	$109.0M
YoY Change	54.58%	84.67%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$9.881M	$5.583M
YoY Change	76.98%	-47.33%
Accrued Expenses	$10.56M	$6.846M
YoY Change	54.18%	59.21%
Deferred Revenue	$669.0K	$681.0K
YoY Change	-1.76%
Short-Term Debt	$0.00	$0.00
YoY Change		-100.0%
Long-Term Debt Due	$200.0K
YoY Change
Total Short-Term Liabilities	$22.46M	$16.56M
YoY Change	35.64%	-20.78%
LONG-TERM LIABILITIES
Long-Term Debt	$48.50M	$23.20M
YoY Change	109.05%	16.58%
Other Long-Term Liabilities	$2.126M	$3.378M
YoY Change	-37.06%	-87.49%
Total Long-Term Liabilities	$2.126M	$3.378M
YoY Change	-37.06%	-92.8%
TOTAL LIABILITIES
Total Short-Term Liabilities	$22.46M	$16.56M
Total Long-Term Liabilities	$2.126M	$3.378M
Total Liabilities	$78.12M	$47.93M
YoY Change	62.99%	-29.31%
SHAREHOLDERS EQUITY
Retained Earnings	-$144.9M	-$99.75M
YoY Change	45.24%
Common Stock	$211.7M	$146.3M
YoY Change	44.74%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$2.854M	$2.854M
YoY Change	0.0%
Treasury Stock Shares	408.1K shares	408.1K shares
Shareholders Equity	$90.31M	$61.03M
YoY Change
Total Liabilities & Shareholders Equity	$168.4M	$109.0M
YoY Change	54.58%	84.67%

Cashflow Statement

Concept	2020 Q1	2019 Q1
OPERATING ACTIVITIES
Net Income	-$17.75M	-$10.78M
YoY Change	64.7%	65.07%
Depreciation, Depletion And Amortization	$20.00K	$21.00K
YoY Change	-4.76%	-12.5%
Cash From Operating Activities	-$6.802M	-$7.998M
YoY Change	-14.95%	34.85%
INVESTING ACTIVITIES
Capital Expenditures	$687.0K	$685.0K
YoY Change	0.29%	74.74%
Acquisitions
YoY Change
Other Investing Activities	$0.00	-$770.0K
YoY Change	-100.0%
Cash From Investing Activities	-$949.0K	-$1.455M
YoY Change	-34.78%	251.45%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$63.86M	$0.00
YoY Change		-100.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$63.93M	-$16.00K
YoY Change	-399637.5%	-100.81%
NET CHANGE
Cash From Operating Activities	-$6.802M	-$7.998M
Cash From Investing Activities	-$949.0K	-$1.455M
Cash From Financing Activities	$63.93M	-$16.00K
Net Change In Cash	$55.94M	-$9.504M
YoY Change	-688.6%	123.57%
FREE CASH FLOW
Cash From Operating Activities	-$6.802M	-$7.998M
Capital Expenditures	$687.0K	$685.0K
Free Cash Flow	-$7.489M	-$8.683M
YoY Change	-13.75%	37.32%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2020Q1	dei	Amendment Flag AmendmentFlag	false
CY2020Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2020Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2020Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2020
CY2020Q1	dei	Document Period End Date DocumentPeriodEndDate	2020-03-31
CY2020Q1	dei	Document Type DocumentType	10-Q
CY2020Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001688757
CY2020Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	23328791	shares
CY2020Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2020Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2020Q1	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2020Q1	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
CY2020Q1	dei	Entity Registrant Name EntityRegistrantName	Establishment Labs Holdings Inc.
CY2020Q1	dei	Entity Shell Company EntityShellCompany	false
CY2020Q1	dei	Entity Small Business EntitySmallBusiness	true
CY2019Q4	esta	Accrued Stock Option Grant Bonus Current AccruedStockOptionGrantBonusCurrent	4212000	USD
CY2020Q1	esta	Accrued Stock Option Grant Bonus Current AccruedStockOptionGrantBonusCurrent	4490000	USD
CY2019Q4	esta	Advisory Board And Board Of Director Liabilities Current AdvisoryBoardAndBoardOfDirectorLiabilitiesCurrent	124000	USD
CY2020Q1	esta	Advisory Board And Board Of Director Liabilities Current AdvisoryBoardAndBoardOfDirectorLiabilitiesCurrent	145000	USD
CY2019Q1	esta	Allocated Sharebased Compensation Expense And Issuance Of Stock And Warrants For Services Or Claims AllocatedSharebasedCompensationExpenseAndIssuanceOfStockAndWarrantsForServicesOrClaims	1836000	USD
CY2020Q1	esta	Allocated Sharebased Compensation Expense And Issuance Of Stock And Warrants For Services Or Claims AllocatedSharebasedCompensationExpenseAndIssuanceOfStockAndWarrantsForServicesOrClaims	1629000	USD
CY2019Q4	esta	Cash Payable For Asset Acquisition Current CashPayableForAssetAcquisitionCurrent	492000	USD
CY2020Q1	esta	Cash Payable For Asset Acquisition Current CashPayableForAssetAcquisitionCurrent	873000	USD
CY2019Q4	esta	Cash Payable For Asset Acquisition Noncurrent CashPayableForAssetAcquisitionNoncurrent	781000	USD
CY2020Q1	esta	Cash Payable For Asset Acquisition Noncurrent CashPayableForAssetAcquisitionNoncurrent	379000	USD
CY2019Q1	esta	Depreciation And Amortization Property Plant And Equipment DepreciationAndAmortizationPropertyPlantAndEquipment	600000	USD
CY2020Q1	esta	Depreciation And Amortization Property Plant And Equipment DepreciationAndAmortizationPropertyPlantAndEquipment	600000	USD
CY2019Q1	esta	Depreciationand Amortization Excluding Debt Discount Premium DepreciationandAmortizationExcludingDebtDiscountPremium	633000	USD
CY2020Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear	695000	USD
CY2020Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	277000	USD
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	24122000	USD
CY2020Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	6232000	USD
CY2019Q1	esta	Noncash Consideration Payable Relatedto Asset Acquisition NoncashConsiderationPayableRelatedtoAssetAcquisition	1257000	USD
CY2020Q1	esta	Depreciationand Amortization Excluding Debt Discount Premium DepreciationandAmortizationExcludingDebtDiscountPremium	833000	USD
CY2020Q1	esta	Employee And Non Employee Service Sharebased Compensation Nonvested Awards Compensation Cost Notyet Recognized Periodfor Recognition EmployeeAndNonEmployeeServiceSharebasedCompensationNonvestedAwardsCompensationCostNotyetRecognizedPeriodforRecognition	P2Y2M12D
CY2019Q4	esta	Line Of Credit Including Interest Payable Current LineOfCreditIncludingInterestPayableCurrent	48142000	USD
CY2020Q1	esta	Line Of Credit Including Interest Payable Current LineOfCreditIncludingInterestPayableCurrent	48529000	USD
CY2020Q1	esta	Noncash Consideration Payable Relatedto Asset Acquisition NoncashConsiderationPayableRelatedtoAssetAcquisition	1257000	USD
CY2019Q1	esta	Noncash Deferred Offering Expense NoncashDeferredOfferingExpense	337000	USD
CY2020Q1	esta	Revenue From Contract With Customer Product Return Period RevenueFromContractWithCustomerProductReturnPeriod	P15D
CY2020Q1	esta	Revenue From Contract With Customer Product Shelf Life RevenueFromContractWithCustomerProductShelfLife	P5Y
CY2020Q1	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	367000	USD
CY2019Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	1996000	USD
CY2019Q1	esta	Sharebased Compensation And Issuance Of Stock Or Warrants For Services And Claims SharebasedCompensationAndIssuanceOfStockOrWarrantsForServicesAndClaims	1836000	USD
CY2020Q1	esta	Sharebased Compensation And Issuance Of Stock Or Warrants For Services And Claims SharebasedCompensationAndIssuanceOfStockOrWarrantsForServicesAndClaims	1629000	USD
CY2020Q1	esta	Noncash Deferred Offering Expense NoncashDeferredOfferingExpense	0	USD
CY2019Q1	esta	Stock Issued During Period Value Warrant Exercises StockIssuedDuringPeriodValueWarrantExercises	56000	USD
CY2019Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	10366000	USD
CY2020Q1	esta	Number Of Manufacturing Facilities NumberOfManufacturingFacilities	2	facility
CY2019Q1	esta	Paymentsto Acquire Assets Including Receivables Held PaymentstoAcquireAssetsIncludingReceivablesHeld	767000	USD
CY2020Q1	esta	Paymentsto Acquire Assets Including Receivables Held PaymentstoAcquireAssetsIncludingReceivablesHeld	0	USD
CY2020Q1	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	2892000	USD
CY2020Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	7991000	USD
CY2019Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	691000	USD
CY2020Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	9881000	USD
CY2019Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	22767000	USD
CY2020Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	21615000	USD
CY2020Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	10555000	USD
CY2019Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	500000	USD
CY2019Q4	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	2080000	USD
CY2020Q1	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	1181000	USD
CY2019Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	10677000	USD
CY2019Q4	us-gaap	Accrued Sales Commission Current AccruedSalesCommissionCurrent	522000	USD
CY2020Q1	us-gaap	Accrued Sales Commission Current AccruedSalesCommissionCurrent	379000	USD
CY2019Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	7522000	USD
CY2020Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	3512000	USD
CY2019Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	21214000	USD
CY2020Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	22799000	USD
CY2019Q1	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	56000	USD
CY2020Q1	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	34000	USD
CY2019Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	1026000	USD
CY2020Q1	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	1575000	USD
CY2019Q1	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	868000	USD
CY2020Q1	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	388000	USD
CY2019Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	200000	USD
CY2020Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	200000	USD
CY2019Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1830721	shares
CY2020Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1746843	shares
CY2019	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	USD
CY2020Q1	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	USD
CY2019Q4	us-gaap	Assets Assets	116531000	USD
CY2020Q1	us-gaap	Assets Assets	168423000	USD
CY2019Q4	us-gaap	Assets Current AssetsCurrent	95839000	USD
CY2020Q1	us-gaap	Assets Current AssetsCurrent	147896000	USD
CY2019Q1	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-225000	USD
CY2020Q1	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-440000	USD
CY2019Q4	us-gaap	Business Combination Contingent Consideration Liability Current BusinessCombinationContingentConsiderationLiabilityCurrent	922000	USD
CY2020Q1	us-gaap	Business Combination Contingent Consideration Liability Current BusinessCombinationContingentConsiderationLiabilityCurrent	482000	USD
CY2019Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	705000	USD
CY2020Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	395000	USD
CY2019Q4	us-gaap	Capital Lease Obligations Current CapitalLeaseObligationsCurrent	258000	USD
CY2020Q1	us-gaap	Capital Lease Obligations Current CapitalLeaseObligationsCurrent	184000	USD
CY2019Q1	us-gaap	Capital Lease Obligations Incurred CapitalLeaseObligationsIncurred	69000	USD
CY2020Q1	us-gaap	Capital Lease Obligations Incurred CapitalLeaseObligationsIncurred	0	USD
CY2020Q1	us-gaap	Capital Lease Obligations Noncurrent CapitalLeaseObligationsNoncurrent	206000	USD
CY2019Q4	us-gaap	Capital Leased Assets Gross CapitalLeasedAssetsGross	1500000	USD
CY2020Q1	us-gaap	Capital Leased Assets Gross CapitalLeasedAssetsGross	1500000	USD
CY2020Q1	us-gaap	Capital Leases Future Minimum Payments Due CapitalLeasesFutureMinimumPaymentsDue	422000	USD
CY2020Q1	us-gaap	Capital Leases Future Minimum Payments Due In Three Years CapitalLeasesFutureMinimumPaymentsDueInThreeYears	39000	USD
CY2020Q1	us-gaap	Capital Leases Future Minimum Payments Due In Two Years CapitalLeasesFutureMinimumPaymentsDueInTwoYears	178000	USD
CY2020Q1	us-gaap	Capital Leases Future Minimum Payments Interest Included In Payments CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments	32000	USD
CY2020Q1	us-gaap	Capital Leases Future Minimum Payments Present Value Of Net Minimum Payments CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments	390000	USD
CY2020Q1	us-gaap	Capital Leases Future Minimum Payments Remainder Of Fiscal Year CapitalLeasesFutureMinimumPaymentsRemainderOfFiscalYear	205000	USD
CY2019Q4	us-gaap	Cash Cash	37655000	USD
CY2020Q1	us-gaap	Cash Cash	93596000	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	52639000	USD
CY2019Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	43135000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	37655000	USD
CY2020Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	93596000	USD
CY2019Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-9504000	USD
CY2020Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	55941000	USD
CY2019Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	0	USD
CY2020Q1	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	0	USD
CY2019Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2020Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2019Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	3571406	shares
CY2020Q1	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	4384473	shares
CY2019Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	21057040	shares
CY2020Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	23735013	shares
CY2019Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	20648970	shares
CY2020Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	23326943	shares
CY2019Q4	us-gaap	Common Stock Value CommonStockValue	147688000	USD
CY2020Q1	us-gaap	Common Stock Value CommonStockValue	211734000	USD
CY2019Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-10712000	USD
CY2020Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-14938000	USD
CY2019Q4	us-gaap	Contract With Customer Asset Accumulated Allowance For Credit Loss ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss	36000	USD
CY2020Q1	us-gaap	Contract With Customer Asset Accumulated Allowance For Credit Loss ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss	44000	USD
CY2019Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	785000	USD
CY2020Q1	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	669000	USD
CY2019Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	1344000	USD
CY2020Q1	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	1405000	USD
CY2019Q1	us-gaap	Cost Of Revenue CostOfRevenue	9526000	USD
CY2020Q1	us-gaap	Cost Of Revenue CostOfRevenue	9003000	USD
CY2019Q1	us-gaap	Depreciation Depreciation	21000	USD
CY2020Q1	us-gaap	Depreciation Depreciation	20000	USD
CY2019Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	3072000	USD
CY2020Q1	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	5001000	USD
CY2019Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.53
CY2020Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.79
CY2019Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-35000	USD
CY2020Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-234000	USD
CY2020Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	6300000	USD
CY2019Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	1923000	USD
CY2020Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	293000	USD
CY2020Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	2141000	USD
CY2020Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	509000	USD
CY2020Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	537000	USD
CY2020Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	863000	USD
CY2020Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	3174000	USD
CY2019Q1	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-400000	USD
CY2020Q1	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-6200000	USD
CY2019Q1	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	-892000	USD
CY2020Q1	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	-5845000	USD
CY2019Q1	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	-32000	USD
CY2020Q1	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	-1929000	USD
CY2019Q1	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-8000	USD
CY2020Q1	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-5000	USD
CY2019Q4	us-gaap	Goodwill Goodwill	465000	USD
CY2020Q1	us-gaap	Goodwill Goodwill	465000	USD
CY2020Q1	us-gaap	Goodwill Acquired During Period GoodwillAcquiredDuringPeriod	0	USD
CY2019Q1	us-gaap	Goodwill And Intangible Asset Impairment GoodwillAndIntangibleAssetImpairment	0	USD
CY2020Q1	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	USD
CY2019Q1	us-gaap	Gross Profit GrossProfit	11252000	USD
CY2020Q1	us-gaap	Gross Profit GrossProfit	15478000	USD
CY2019Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-10735000	USD
CY2020Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-17528000	USD
CY2019Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	44000	USD
CY2020Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	231000	USD
CY2019Q1	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	87000	USD
CY2020Q1	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	1000	USD
CY2019Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-619000	USD
CY2020Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	366000	USD
CY2019Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	2883000	USD
CY2020Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	171000	USD
CY2019Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	1142000	USD
CY2020Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	40000	USD
CY2019Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-1744000	USD
CY2020Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-438000	USD
CY2019Q1	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	11000	USD
CY2020Q1	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	0	USD
CY2019Q1	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	161000	USD
CY2020Q1	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	19000	USD
CY2019Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	826000	USD
CY2020Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	660000	USD
CY2019Q4	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	291000	USD
CY2020Q1	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	291000	USD
CY2019Q4	us-gaap	Intangible Assets Gross Excluding Goodwill IntangibleAssetsGrossExcludingGoodwill	5364000	USD
CY2020Q1	us-gaap	Intangible Assets Gross Excluding Goodwill IntangibleAssetsGrossExcludingGoodwill	5606000	USD
CY2019Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	3441000	USD
CY2020Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	3465000	USD
CY2019Q1	us-gaap	Interest Expense InterestExpense	2242000	USD
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1837576	shares
CY2020Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1781431	shares
CY2020Q1	us-gaap	Interest Expense InterestExpense	2146000	USD
CY2019Q1	us-gaap	Interest Paid Net InterestPaidNet	1402000	USD
CY2019Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	21954000	USD
CY2020Q1	us-gaap	Interest Paid Net InterestPaidNet	1734000	USD
CY2019Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	300000	USD
CY2020Q1	us-gaap	Inventory Write Down InventoryWriteDown	137000	USD
CY2020Q1	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	19585000	USD
CY2019Q4	us-gaap	Inventory Net InventoryNet	28660000	USD
CY2020Q1	us-gaap	Inventory Net InventoryNet	25512000	USD
CY2019Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	5506000	USD
CY2020Q1	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	4607000	USD
CY2020Q1	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	500000	USD
CY2019Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	1200000	USD
CY2020Q1	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	1320000	USD
CY2019Q1	us-gaap	Inventory Write Down InventoryWriteDown	-83000	USD
CY2019Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	6000	USD
CY2020Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	8000	USD
CY2019Q1	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	300000	USD
CY2020Q1	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	300000	USD
CY2019Q4	us-gaap	Liabilities Liabilities	76917000	USD
CY2020Q1	us-gaap	Liabilities Liabilities	78116000	USD
CY2019Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	116531000	USD
CY2020Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	168423000	USD
CY2019Q4	us-gaap	Liabilities Current LiabilitiesCurrent	23242000	USD
CY2020Q1	us-gaap	Liabilities Current LiabilitiesCurrent	22460000	USD
CY2019Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-16000	USD
CY2020Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	63926000	USD
CY2019Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1455000	USD
CY2020Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-949000	USD
CY2019Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-7998000	USD
CY2020Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-6802000	USD
CY2019Q1	us-gaap	Net Income Loss NetIncomeLoss	-10779000	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-17759000	USD
CY2019Q1	us-gaap	Noncash Or Part Noncash Acquisition Fixed Assets Acquired1 NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1	1104000	USD
CY2020Q1	us-gaap	Noncash Or Part Noncash Acquisition Fixed Assets Acquired1 NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1	0	USD
CY2020Q1	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1	segment
CY2020Q1	us-gaap	Number Of Reporting Units NumberOfReportingUnits	1	reportingunit
CY2019Q1	us-gaap	Operating Expenses OperatingExpenses	19640000	USD
CY2020Q1	us-gaap	Operating Expenses OperatingExpenses	23183000	USD
CY2019Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-8388000	USD
CY2020Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-7705000	USD
CY2020Q1	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	3667000	USD
CY2020Q1	us-gaap	Operating Leases Future Minimum Payments Due In Five Years OperatingLeasesFutureMinimumPaymentsDueInFiveYears	373000	USD
CY2020Q1	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	381000	USD
CY2020Q1	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	432000	USD
CY2020Q1	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	588000	USD
CY2020Q1	us-gaap	Operating Leases Future Minimum Payments Due Thereafter OperatingLeasesFutureMinimumPaymentsDueThereafter	1365000	USD
CY2020Q1	us-gaap	Operating Leases Future Minimum Payments Remainder Of Fiscal Year OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear	528000	USD
CY2019Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	67000	USD
CY2019Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	67000	USD
CY2020Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	2821000	USD
CY2019Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	368000	USD
CY2020Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	362000	USD
CY2019Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	672000	USD
CY2020Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	591000	USD
CY2020Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	2821000	USD
CY2019Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	2199000	USD
CY2020Q1	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	2024000	USD
CY2019Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	2461000	USD
CY2020Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	2126000	USD
CY2019Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-304000	USD
CY2020Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-6196000	USD
CY2019Q4	us-gaap	Other Sundry Liabilities Noncurrent OtherSundryLiabilitiesNoncurrent	336000	USD
CY2020Q1	us-gaap	Other Sundry Liabilities Noncurrent OtherSundryLiabilitiesNoncurrent	342000	USD
CY2019Q1	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	56000	USD
CY2020Q1	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	34000	USD
CY2019Q1	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	3000	USD
CY2020Q1	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	262000	USD
CY2019Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	685000	USD
CY2020Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	687000	USD
CY2019Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	6757000	USD
CY2020Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	7173000	USD
CY2019Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	84000	USD
CY2020Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	181000	USD
CY2019Q1	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	58000	USD
CY2020Q1	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	0	USD
CY2019Q4	us-gaap	Product Warranty Accrual Classified Current ProductWarrantyAccrualClassifiedCurrent	313000	USD
CY2020Q1	us-gaap	Product Warranty Accrual Classified Current ProductWarrantyAccrualClassifiedCurrent	326000	USD
CY2020Q1	us-gaap	Property Plant And Equipment Estimated Useful Lives PropertyPlantAndEquipmentEstimatedUsefulLives	P50Y
CY2019Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	23940000	USD
CY2020Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	24226000	USD
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	16418000	USD
CY2020Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	16235000	USD
CY2019Q1	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	112000	USD
CY2020Q1	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	599000	USD
CY2019Q1	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	102000	USD
CY2020Q1	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	76000	USD
CY2019Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3584000	USD
CY2020Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4199000	USD
CY2019Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-127125000	USD
CY2020Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-144884000	USD
CY2019Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	20778000	USD
CY2020Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	24481000	USD
CY2019Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	16056000	USD
CY2020Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	18984000	USD
CY2020Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	400000	USD
CY2020Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	14.43
CY2020Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	87375	shares
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	14.54
CY2020Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	15.18
CY2020Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	70953	shares
CY2020Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	14.20
CY2020Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue	5300000	USD
CY2020Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	742711	shares
CY2020Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice	8.33
CY2020Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	4.56
CY2020Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	25.03
CY2019Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y22D
CY2020Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y
CY2020Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	39723	shares
CY2019Q1	us-gaap	Stock Issued During Period Value Purchase Of Assets StockIssuedDuringPeriodValuePurchaseOfAssets	337000	USD
CY2019Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	1836000	USD
CY2020Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	1629000	USD
CY2019Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	84000	USD
CY2020Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	181000	USD
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	69485000	USD
CY2019Q1	us-gaap	Stockholders Equity StockholdersEquity	61030000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	39614000	USD
CY2020Q1	us-gaap	Stockholders Equity StockholdersEquity	90307000	USD
CY2019Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	408070	shares
CY2020Q1	us-gaap	Treasury Stock Shares TreasuryStockShares	408070	shares
CY2019Q4	us-gaap	Treasury Stock Value TreasuryStockValue	2854000	USD
CY2020Q1	us-gaap	Treasury Stock Value TreasuryStockValue	2854000	USD
CY2019Q1	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	-32000	USD
CY2020Q1	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	-1929000	USD
CY2019Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	20495671	shares
CY2020Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	22456365	shares
CY2020Q1	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:4px;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Concentration of Credit Risk and Other Risks and Uncertainties</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#231f20;">Financial instruments that potentially subject the Company to a concentration of credit risk consist principally of cash and accounts receivable. The majority of the Company’s cash is held at two financial institutions in the United States. Balances in the Company’s cash accounts exceed the Federal Deposit Insurance Corporation, or FDIC, limit of $250,000. The Company has not experienced any losses to its deposits of cash.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#231f20;">All of the Company’s revenue has been derived from sales of its products in international markets, principally Europe, the Middle East, Latin America, and Asia. In the international markets in which the Company participates, the Company uses a combination of distributors and makes direct sales to customers. The Company performs ongoing credit evaluations of its distributors and customers, does not require collateral, and maintains allowances for potential credit losses on customer accounts when deemed necessary.</font></div><div style="line-height:120%;padding-bottom:8px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">During the </font><font style="font-family:Arial;font-size:10pt;">three</font><font style="font-family:Arial;font-size:10pt;"> months ended </font><font style="font-family:Arial;font-size:10pt;">March 31, 2020</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">2019</font><font style="font-family:Arial;font-size:10pt;">, no customers accounted for more than 10% of the Company’s revenue. Substantially all of the Company’s revenues are derived from the sale of Motiva Implants. </font><font style="font-family:Arial;font-size:10pt;">One</font><font style="font-family:Arial;font-size:10pt;"> customer accounted for </font><font style="font-family:Arial;font-size:10pt;">12.0%</font><font style="font-family:Arial;font-size:10pt;"> and another customer accounted for </font><font style="font-family:Arial;font-size:10pt;">11.0%</font><font style="font-family:Arial;font-size:10pt;"> of the Company’s trade accounts receivable balance as of </font><font style="font-family:Arial;font-size:10pt;">March 31, 2020</font><font style="font-family:Arial;font-size:10pt;">. One customer accounted for </font><font style="font-family:Arial;font-size:10pt;">10.2%</font><font style="font-family:Arial;font-size:10pt;"> of the Company’s trade accounts receivable balance as of </font><font style="font-family:Arial;font-size:10pt;color:#231f20;">December 31, 2019</font><font style="font-family:Arial;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:8px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company relies on NuSil Technology, LLC, or NuSil, as the sole supplier of medical-grade silicone used in Motiva Implants. During the </font><font style="font-family:Arial;font-size:10pt;">three</font><font style="font-family:Arial;font-size:10pt;"> months ended </font><font style="font-family:Arial;font-size:10pt;">March 31, 2020</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">2019</font><font style="font-family:Arial;font-size:10pt;">, the Company had purchases of </font><font style="font-family:Arial;font-size:10pt;">$5.0 million</font><font style="font-family:Arial;font-size:10pt;">, or </font><font style="font-family:Arial;font-size:10pt;">64.9%</font><font style="font-family:Arial;font-size:10pt;"> of total purchases, and </font><font style="font-family:Arial;font-size:10pt;">$3.7 million</font><font style="font-family:Arial;font-size:10pt;">, or </font><font style="font-family:Arial;font-size:10pt;">62.9%</font><font style="font-family:Arial;font-size:10pt;"> of total purchases, respectively, from NuSil. As of </font><font style="font-family:Arial;font-size:10pt;">March 31, 2020</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;color:#231f20;">December 31, 2019</font><font style="font-family:Arial;font-size:10pt;">, we had an outstanding balance owed to this vendor of </font><font style="font-family:Arial;font-size:10pt;">$0.6 million</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">$2.7 million</font><font style="font-family:Arial;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company’s future results of operations involve a number of risks and uncertainties. Factors that could affect the Company’s future operating results and cause actual results to vary materially from expectations include, but are not limited to, uncertainty of regulatory approval of the Company’s current and potential future products, uncertainty of market acceptance of the Company’s products, competition from substitute products and larger companies, securing and protecting proprietary technology, strategic relationships and dependence on key individuals and sole source suppliers. </font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Products developed by the Company require clearances from the FDA or other international regulatory agencies prior to commercial sales. There can be no assurance that the products will receive the necessary clearances. If the Company was denied clearance, clearance was delayed, or the Company was unable to maintain its existing clearances, these developments could have a material adverse impact on the Company.</font></div></div>
CY2020Q1	us-gaap	Derivatives Embedded Derivatives DerivativesEmbeddedDerivatives	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:4px;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Debt and Embedded Derivatives</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company applies the accounting standards for derivatives and hedging and for distinguishing liabilities from equity when accounting for hybrid contracts. The Company accounts for convertible debt instruments when the Company has determined that the embedded conversion options should not be bifurcated from their host instruments in accordance with ASC 470-20 </font><font style="font-family:Arial;font-size:10pt;font-style:italic;">Debt with Conversion and Other Options</font><font style="font-family:Arial;font-size:10pt;"> (see Note 6).</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company uses option pricing valuation models to determine the fair value of embedded derivatives and records any change in fair value as a component of other income or expense in the condensed consolidated statements of operations (see Note 5).</font></div></div>
CY2020Q1	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:4px;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#231f20;">The preparation of financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Significant accounting </font><font style="font-family:Arial;font-size:10pt;">estimates and management judgments reflected in the condensed </font><font style="font-family:Arial;font-size:10pt;color:#231f20;">consolidated</font><font style="font-family:Arial;font-size:10pt;"> financial statements include items such as accounts receivable valuation and allowances, inventory valuation and allowances, valuation of acquired intangible assets, valuation of derivatives, estimation of assets’ useful lives and valuation of deferred income tax assets, including tax valuation allowances. Estimates are based</font><font style="font-family:Arial;font-size:10pt;color:#231f20;"> on historical experience, where applicable, and other assumptions believed to be reasonable by management. Actual results may differ from those estimates under different assumptions or conditions.</font></div></div>

Files In Submission

Name	View Source	Status
0001688757-20-000027-index-headers.html	Edgar Link	pending
0001688757-20-000027-index.html	Edgar Link	pending
0001688757-20-000027.txt	Edgar Link	pending
0001688757-20-000027-xbrl.zip	Edgar Link	pending
esta-20200331.xml	Edgar Link	completed
esta-20200331.xsd	Edgar Link	pending
esta-20200331_cal.xml	Edgar Link	unprocessable
esta-20200331_def.xml	Edgar Link	unprocessable
esta-20200331_lab.xml	Edgar Link	unprocessable
esta-20200331_pre.xml	Edgar Link	unprocessable
establishmentlabs10q_2020q1.htm	Edgar Link	pending
exhibit311q12020.htm	Edgar Link	pending
exhibit312q12020.htm	Edgar Link	pending
exhibit321q12020.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ESTA
ESTABLISHMENT LABS HOLDINGS INC. Stock $esta

2020 Q1 Form 10-Q Financial Statement

#000168875720000027 Filed on May 08, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ESTA ESTABLISHMENT LABS HOLDINGS INC. Stock $esta

2020 Q1 Form 10-Q Financial Statement

#000168875720000027 Filed on May 08, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ESTA
ESTABLISHMENT LABS HOLDINGS INC. Stock $esta